The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Abstract
Background/aims A double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) was conducted in 180 patients with primary biliary cirrhosis (PBC) to define the efficacy and safety of UDCA. Efficacy was assessed by time to treatment failure defined as death; liver transplantation; histological progression; development of varices, ascites, or encephalopathy; doubling of total serum bilirubin levels; progression of fatigue or pruritus; drug toxicity; or voluntary withdrawal. Methods Patients with well-defined PBC underwent complete history, physical examination, liver chemistries, ultrasonography, upper endoscopy, and liver biopsy at entry as well as at 2 years. Liver chemistries were determined every 3 months. Results In patients receiving UDCA, treatment failure was delayed compared with the placebo-treated group (P = 0.0003, log rank test). Seven patients receiving UDCA died or required transplantation compared with 12 in the placebo group (P = 0.18). No patients discontinued UDCA because of side effects of toxicity. Conclusions UDCA was extraordinarily safe and well tolerated, and its use was associated with delayed progression of the disease as defined in this study. However, the lack of effects on symptoms, histology, and the need for liver transplantation or survival indicate that further evaluation is necessary to determine the ultimate role of UDCA in the treatment of PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its use is already recommended for all patients with PBC by the American Association for the Study of Liver Diseases (AASLD) and EASL, as well as in this new guideline [35,[112][113][114][115][116][117][118][119][120][121].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [113]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
A class of rank test procedures for censored survival data
HARRINGTON, D. P., & FLEMING, T. R. (1982) · Biometrika · doi:10.1093/biomet/69.3.553 · Cited by 1,184
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Self-citationIS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 536
Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis
Christensen, E., Neuberger, J., Crowe, J., Altman, D. G., Popper, H., Portmann, B., Doniach, D., Ranek, L., Tygstrup, N., & Williams, R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90213-6 · Cited by 423
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“UDCA has been demonstrated to markedly decrease serum bilirubin, AP, cGT, cholesterol and immunoglobulin M levels, and to ameliorate histological features in patients with PBC in comparison to placebo treatment [13–17] although no significant effects on fatigue or pruritus were observed in these large trials.”
ResultHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Metadata
- Authors
- Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., Lesage, G., Rossi, S. S., & Hofmann, A. F.
- Affiliations
- Mayo Clinic (US)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1994-05
- Volume
- 106
- Issue
- 5
- Pages
- 1284-1290
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1584416327
- Cited by
- 487
- References
- 23
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 6 · 2023: 4 · 2022: 10 · 2021: 5 · 2020: 9 · 2019: 17 · 2018: 15 · 2017: 19 · 2016: 11 · 2015: 8 · 2014: 12 · 2013: 4 · 2012: 8
- FWCI
- 20.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, treatment efficacy, drug safety, disease progression, liver transplantation, mortality, serum bilirubin, pruritus, fatigue, bile acid therapy
- MeSH terms
- Adult, Bilirubin, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Ursodeoxycholic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. https://app.cochat.ai/papers/10.1016/0016-5085(94)90021-3
- The paper
- Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., Lesage, G., Rossi, S. S., & Hofmann, A. F. (1994). Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. https://doi.org/10.1016/0016-5085(94)90021-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.